VELA Investment Management LLC Buys 12,983 Shares of Supernus Pharmaceuticals, Inc. $SUPN

VELA Investment Management LLC boosted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 25.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,594 shares of the specialty pharmaceutical company’s stock after purchasing an additional 12,983 shares during the period. VELA Investment Management LLC owned about 0.11% of Supernus Pharmaceuticals worth $3,004,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in SUPN. Bank of America Corp DE lifted its stake in shares of Supernus Pharmaceuticals by 37.2% in the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after acquiring an additional 193,479 shares during the last quarter. Mystic Asset Management Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at $1,181,000. BlackRock Inc. bought a new stake in Supernus Pharmaceuticals during the 2nd quarter worth $434,871,000. Allworth Financial LP bought a new stake in Supernus Pharmaceuticals during the 2nd quarter worth $2,357,000. Finally, Rice Hall James & Associates LLC acquired a new position in Supernus Pharmaceuticals in the 2nd quarter worth about $22,800,000.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $62.83.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $43.53 on Monday. The firm has a market cap of $2.53 billion, a P/E ratio of -22.67, a P/E/G ratio of 0.80 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 12-month low of $42.45 and a 12-month high of $59.68. The business has a fifty day simple moving average of $46.69 and a 200 day simple moving average of $48.39.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm’s quarterly revenue was up 32.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.40 earnings per share. As a group, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.